clinical trial · NCT05754450
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II
Leukocyte Adhesion DeficiencyAVTX-803
brief summary
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
started
Apr 10, 2023
primary completion
Dec 31, 2024
completion
Dec 31, 2024
last updated
Nov 1, 2024
official title
A Phase 3, Open-Label, Extension Study to Assess the Long-term Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol